Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 5/20 | 0.65 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | MIF | P14174 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7537416 | 0.90 | MEN1 (0.64) | PKMSCN9AMAPTTP53MIF | |
| SCHEMBL7537163 | 0.86 | SCN9A (0.63) | PKMSCN9AMAPTTP53MIF | |
| SCHEMBL7538875 | 0.80 | MEN1 (0.65) | PKMSCN9AMAPTTP53POLB | |
| SCHEMBL13076064 | 0.80 | PKM (0.61) | PKMMAPTTP53POLBMEN1 | |
| SCHEMBL7537999 | 0.79 | PKM (1.00) | PKMMAPTTP53POLBMEN1 | |
| SCHEMBL14896265 | 0.79 | SCN9A (1.00) | SCN9AMIFNPC1 | |
| SCHEMBL14895995 | 0.78 | SCN9A (0.84) | PKMSCN9AMAPTTP53IDO1 | |
| SCHEMBL7541439 | 0.76 | PKM (0.58) | PKMSCN9AMAPTTP53POLB | |
| SCHEMBL14895674 | 0.75 | SCN9A (0.84) | SCN9A | |
| SCHEMBL7534545 | 0.74 | MEN1 (0.73) | PKMTP53POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007608-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | AGIOS PHARMACEUTICALS INC (US) | 2017-01-12 | — | — | US | disclosed |
| EP-2427441-B1 | PKM2 ACTIVATORS FOR USE IN THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20140249150-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | AGIOS PHARMACEUTICALS, INC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8501953-B2 | PKM2 modulators for use in the treatment of cancer | AGIOS PHARMACEUTICALS, INC (US) | 2013-08-06 | — | — | US | disclosed |
| WO-2013056153-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | KUNG CHARLES (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20120122849-A1 | PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122849-A1 | PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER | PDK2, PDK1, PDK3 | PKM 5/4885SCN9A 3720/4885MAPT 3769/4885 |
| US-20140249150-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | PDK1, PC, PDK2 | PKM 11/4885SCN9A 3577/4885MAPT 2681/4885 |
| US-20170007608-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | PDK1, PC, PDK2 | PKM 11/4885SCN9A 3577/4885MAPT 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.